Chronic Lymphocytic Leukemia Therapeutics Market Opportunity Analysis 2018- 2026
Chronic lymphocytic leukemia (CLL) is a most common type of leukemia found in adults. It is a kind of malignancy characterized by production of abnormal white blood cells in the bone marrow. Symptoms include, swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Although CLL is rarely seen in children and people under age 40, it is more prevalent in geriatric population. Moreover, causes of CLL are largely unknown and it is more severe than acute leukemia. The prevalence of CLL is high in males than females. Although, the incidence of this disorder is higher in white population than Asian populations, the precise cause for this cannot be explained.
Chronic lymphocytic leukemia (CLL) is a most common type of leukemia found in adults. It is a kind of malignancy characterized by production of abnormal white blood cells in the bone marrow. Symptoms include, swelling of the lymph nodes, fatigue, fever, infection, pain beneath the ribs, and weight loss. Although CLL is rarely seen in children and people under age 40, it is more prevalent in geriatric population. Moreover, causes of CLL are largely unknown and it is more severe than acute leukemia. The prevalence of CLL is high in males than females. Although, the incidence of this disorder is higher in white population than Asian populations, the precise cause for this cannot be explained.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Chronic</strong> <strong>Lymphocytic</strong> <strong>Leukemia</strong><br />
<strong>Therapeutics</strong> <strong>Market</strong> - Size, Share,<br />
Outlook, and <strong>Opportunity</strong> <strong>Analysis</strong>,<br />
<strong>2018</strong> - <strong>2026</strong><br />
<strong>Chronic</strong> <strong>Lymphocytic</strong> <strong>Leukemia</strong> <strong>Therapeutics</strong> <strong>Market</strong>, by Drug (Idelalisib (Zydelig),<br />
Venetoclax (Venclexta), Ibrutinib (Imbruvica), Ofatumumab (Arzerra), Fludarabine<br />
(Fludara), Obinutuzumab (Gazyva), Bendamustine Hydrochloride (Treanda), and<br />
Others) and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and<br />
Online Pharmacies) and By Region (North America, Latin America, Europe, Asia<br />
Pacific, Middle East and Africa ) - Size, Share, Outlook, and <strong>Opportunity</strong> <strong>Analysis</strong><br />
<strong>2018</strong>- <strong>2026</strong><br />
<strong>Chronic</strong> lymphocytic leukemia (CLL) is a most common type of leukemia found in adults. It is a<br />
kind of malignancy characterized by production of abnormal white blood cells in the bone<br />
marrow. Symptoms include, swelling of the lymph nodes, fatigue, fever, infection, pain beneath<br />
the ribs, and weight loss. Although CLL is rarely seen in children and people under age 40, it is<br />
more prevalent in geriatric population. Moreover, causes of CLL are largely unknown and it is<br />
more severe than acute leukemia. The prevalence of CLL is high in males than females.<br />
Although, the incidence of this disorder is higher in white population than Asian populations, the<br />
precise cause for this cannot be explained.<br />
The diagnosis of CLL includes Blood Cell Count and Examination, Bone Marrow Examination for<br />
patients followed by treatment. The treatment includes single or combination drug therapy,<br />
targeted therapies, monoclonal antibody therapies, white blood cell (neutrophil) growth factors.<br />
In addition to this, there are radiation therapy and splenectomy which are rarely used for the<br />
treatment.<br />
Request Sample Copy of this Business Report @<br />
https://www.coherentmarketinsights.com/insight/request-sample/1315<br />
High prevalence of CLL coupled with its high mortality rate, demonstrates the unmet market<br />
need for better therapeutics. According to the American Cancer Society (ACS) estimates, around<br />
20,110 new cases of chronic lymphocytic leukemia and 4,660 deaths from CLL is expected in<br />
year 2017 in U.S. Furthermore, high prevalence of CLL in geriatric population is expected to<br />
increase demand for chronic lymphocytic leukemia therapeutics. According to the United Nations
data, in 2015, around 901 million people in the world were over 60 years of age and this number<br />
is expected to reach 1.4 billion by 2030 and to 2.1 billion by 2050.<br />
Furthermore, increasing number of incidences of comorbidities, especially among geriatric<br />
population and launch of new pipeline drugs are major factors contributing to growth of the<br />
chronic lymphocytic leukemia therapeutics market. For instance, on December 8, 2015, Bendeka<br />
injection—manufactured under the collaboration of Teva Pharmaceuticals Industries Ltd. and<br />
Eagle Pharmaceuticals Inc. acquired approval from FDA for the treatment of patients with CLL<br />
and indolent B-cell non-Hodgkin lymphoma (NHL) — progressed during or within six months of<br />
treatment with rituximab or a rituximab-containing regimen.<br />
On the basis of region, the chronic lymphocytic leukemia therapeutics market is segmented into<br />
North America, Europe, Latin America, Asia Pacific, Middle East, and Africa. North America<br />
accounted for the largest market share in 2016 due to the presence of breakthrough pipeline<br />
drugs. For instance, the drug Acalabrutinib—manufactured by Acerta Pharma BV—is under phase<br />
2 clinical trial for the treatment of CLL and small lymphocytic lymphoma (SLL) and the study is<br />
expected to complete in January 2019<br />
Browse More About the Keyword <strong>Market</strong> Study @<br />
https://www.coherentmarketinsights.com/ongoing-insight/image-guided-therapy-systemmarket-1315<br />
Report includes chapters which deeply display the following deliverable about industry:<br />
• Image Guided Therapy System <strong>Market</strong> Research Objective and Assumption<br />
• Image Guided Therapy System <strong>Market</strong> Purview - Report Description, Executive Summary, and<br />
Coherent <strong>Opportunity</strong> Map (COM)<br />
• Image Guided Therapy System <strong>Market</strong> Dynamics, Regulations, and Trends <strong>Analysis</strong> - <strong>Market</strong><br />
Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system<br />
Launch/Approvals, Value Chain <strong>Analysis</strong>, Porter’s <strong>Analysis</strong>, and PEST <strong>Analysis</strong><br />
• Global Image Guided Therapy System <strong>Market</strong>, By Regions<br />
• Image Guided Therapy System <strong>Market</strong> Competition by Manufacturers including Production, Share,<br />
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.<br />
• Image Guided Therapy System <strong>Market</strong> Manufacturers Profiles/<strong>Analysis</strong> including Company Basic<br />
Information, Manufacturing Base and Its Competitors.<br />
• Image Guided Therapy System <strong>Market</strong> Manufacturing Cost <strong>Analysis</strong> including Key Raw Materials<br />
and Key Suppliers of Raw Materials.<br />
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials<br />
Sourcing and Downstream Buyers<br />
• <strong>Market</strong>ing Strategy <strong>Analysis</strong>, Distributors/Traders including <strong>Market</strong>ing Channel, <strong>Market</strong> Positioning<br />
and Distributors/Traders List.<br />
• <strong>Market</strong> Effect Factors <strong>Analysis</strong> including Technology Progress/Risk, Consumer Needs/Customer<br />
Preference Change and Economic/Political Environmental Change.<br />
• Image Guided Therapy System <strong>Market</strong> Forecast including Production, Consumption, Import and
Export Forecast by Type, Applications and Region.<br />
• Research Findings and Conclusion<br />
Table of Contents of Keyword <strong>Market</strong> Report:<br />
1. Research Objective and assumption<br />
2. <strong>Market</strong> Purview<br />
3. <strong>Market</strong> Dynamics, Regulations, and Trends <strong>Analysis</strong><br />
4. Keyword <strong>Market</strong>, By Advanced Water Meters, 2017 - 2025 (USD Million)<br />
5. Keyword <strong>Market</strong>, By Service, 2017 - 2025 (USD Million)<br />
6. Keyword <strong>Market</strong>, By Solution, 2017 - 2025 (USD Million)<br />
7. Keyword <strong>Market</strong>, By Regions, 2017 - 2025 (USD Million)<br />
8. Competitive Landscape<br />
Ask for Discount before Buying @<br />
https://www.coherentmarketinsights.com/insight/request-discount/1320<br />
About Coherent <strong>Market</strong> Insights:<br />
Coherent <strong>Market</strong> Insights is a prominent market research and consulting firm offering action-ready<br />
syndicated research reports, custom market analysis, consulting services, and competitive analysis<br />
through various recommendations related to emerging market trends, technologies, and potential<br />
absolute dollar opportunity.<br />
Contact Us:<br />
Mr. Shah<br />
Coherent <strong>Market</strong> Insights<br />
1001 4th Ave,<br />
#3200<br />
Seattle, WA 98154<br />
Tel: +1-206-701-6702<br />
Email: sales@coherentmarketinsights.com
Change language